Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit
Rhea-AI Summary
Oyster Point Pharma (Nasdaq: OYST) will participate in the virtual LifeSci Partners Genetic Medicines Summit on June 22, 2021, at 2:00 p.m. ET. The event aims to showcase the company's innovative approaches to treating ophthalmic diseases. Interested parties can access the live webcast through the 'Investors and News' section of their website. As a clinical-stage biopharmaceutical firm, Oyster Point Pharma is dedicated to the discovery and commercialization of first-in-class therapies targeted at ophthalmic conditions.
Positive
- None.
Negative
- None.
News Market Reaction – OYST
In the trading session that priced this news, OYST declined 1.74%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the LifeSci Partners Genetic Medicines Summit on Tuesday, June 22, 2021, at 2:00 p.m. ET.
To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.
About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases.
Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(213) 262-9390
sseapy@realchemistry.com